Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SVACF new HOD on the offer. Keeping this on watch going into power hour
Nice volume today with SVACF wouldn't be surprised if we started to see this move north if this momentum can carry over to next week in my opinion.
SVACF on the move this morning. Seeing heavy volume. This volume could drive the price higher in my opinion. Good entry levels below $0.17?
SVACF picking up steam. plus 5% and rumors of big news http://bit.ly/1G35L8G
SVACF spread tightening. Watch for this to potentially catch momentum this afternoon. New HOD on the offer and $0.18s look thin in my opinion.
Yep buys are still coming in. Volume looks good today. $0.17s look like a good buying opp imo.
Yep $0.18s are going.. This saw $0.20+ not too long ago. wouldn't be surprised with how thin l2 looks if we see those levels sometime in the near future imo.
SVACF trading starting to pick up.. Watching for the bounce
Yeah I agree Jason. Frost seems to have a lot of success in the biotech sector and if he's putting his face behind SVACF that only means good things for this company.
SVACF is a company presenting a new game-changing treatment that is a new third-generation hepatitis B (HBV) vaccine – SciVac’s Sci-B-Vac. It is effective, it has currently been approved in 10 countries throughout the globe, and it is proven 98% effective
SVACF a nice bit of information from the link posted yesterday: August 5, former Chairman of Teva Pharmaceuticals (TEVA) and current CEO and Chaiman of Opko Health (OPK) Phillip Frost closed a deal with SciVac that brought it public and immediately available to investors under the symbol SVACF. Frost owns 45% of the company.
Yes sir. Let's hope it keeps up. I'm out for now, heading to grab some food. Talk later
SciVac Therapeutics (SVACF)
0.189 ? 0.004 (2.16%)
Volume: 201,900 @ 3:57:05 PM ET
Bid Ask Day's Range
0.182 0.186 0.18 - 0.19
SVACF Detailed Quote Wiki
Yes I saw the same. In any case, I think the interest is growing
Agreed. You see how at the end of the day NITE tried to come in at 186??? What's up with that?!
Nice close today
Another nice day of trading for SVACF. Some nice buys came in late makes me believe this could go higher tomorrow IMO.
True. In either case, the chart doesn't look half bad for a solid move in my opinion. It wasn't that long ago when SVACF was in the 20's so I'm hopeful especially if Frost is involved.
Agreed, it doesn't look like there's much hold after breaking through the market-makers. JMO.
IDK man I think it would need to see some consistent trading at 19 for that to happen. It's weird that when 19s get hit, it immediately gets undercut. Hearing some news rumors though so hopefully if this IS a short, the squeeze will be sweet sweet revenge lol.
CSTI and NITE holding the offer right now. I think if it can push through these, SVACF could see 19/20. Just my opinion
Yeah, saw a lot of buys coming in at $0.1895 not too long ago!
SVACF's flagship product is a Hepatitis B vaccine called Sci-B-Vac. Hepatitis B transfers from carrier to carrier through sexual contact, blood contamination and from mother to child. The virus gets into and replicates in hepatocytes, which are the primary functioning cell in the human liver. This invasion of hepatocyte cells leads to an immune response, during which the immune system attacks infected cells, causing damage not only to the infected cells, but also to wider liver function.
Saw that. Once 19s go. 191's look thin. Hoping to see .20 by next week fingers crossed.
$0.185s gone.. new HOD $0.189s up on the offer for SVACF
TY! Wow clinical tests show the vaccine to be 100% on newborns. I really like this piece of information from this report:
"SVACF currently has a market cap of about $150 million with current sales of about $10M a year in vaccine. If Sci-B-Vac™ successfully penetrates Glaxo’s Engerix market of over $1B a year to the tune of even 30%, that translates to $300M in sales annually."
Yeah I agree some nice accumulation building between $0.16-$0.18
Towards the end of last year, we got word that Dr Phillip Frost, chairman and CEO of Opko Health, Inc. (OPK), was looking to restructure then private company SciVac (now SciVac Therapeutics Inc. (SVACF)) into a public entity. Little more was heard of the matter until March 2015, when gold and precious metals exploration company Levon Resources Ltd announced that it had entered into an agreement pursuant to which Levon would acquire 100% of the issued and outstanding ordinary shares of SciVac. OPKO had a 45% stake in SciVac, and so the deal would see current SciVac owners take 68.4% of the outstanding shares of the new company after its close, and Opko take a little over 30%. At first glance the arrangement can seem a little bit convoluted, but a closer look reveals it is very similar in structure to a number of other public shell spins Frost has orchestrated in the past.
http://finance.yahoo.com/news/frost-closes-scivac-deal-potential-041100739.html
Yeah no problem found it here http://bit.ly/1LtPABg GLTY
Rate Hike Concerns Have Not Affected These Biotechnology Stocks
CORAL GABLES, FL / ACCESSWIRE / October 15, 2015 / On Wednesday Richmond Federal Reserve President Jeffrey Lacker stated a brief occurrence of upsetting economic information that has done little to alter his outlook for the U.S economy. Lacker, who voted for an interest rate increase in September against the majority of Fed policymakers who choose to keep rates steady, stated he has not decided on how he will vote at the Oct. 27th-28th meeting.
Although he was not persuaded much by a slowdown in job growth and weaker-than-expected retail sales in September, "It doesn't change my outlook much," he told Fox Business in an interview. In contrast to what many had speculated during late September, the space for biotechnology stocks has seen a much more focused approach by investors. Though overall the larger, index driving company stocks have seen consolidation during recent weeks, companies like CASI Pharmaceuticals, Inc. , Alphatec Holdings, Inc., and SciVac Therapeutics Inc. (SVACF) have actually seen an increase in both intra-day prices and comparative volume.
---------
---------
SciVac Therapeutics Inc. (SVACF) whose headquarters are located in Rehovot Israel, is in the business of developing, manufacturing and promoting biological products for human healthcare. The Company's flagship product, Sci-B-Vac(TM), is a recombinant 3rd generation hepatitis B vaccine. SVACF announced recently that its wholly-owned subsidiary SciVac Ltd. has obtained the go-ahead from the Israeli Ministry of Health to progress further on all standard manufacturing involving labeling and release of Sci-B-Vac(TM) to the market. This is after corrective actions were given to the automated labeling system and an overview of the Company's facilities earlier in the month of September. SVACF has seen highs this week of $0.0195, which is up roughly 13% from last Friday's. In previous coverage, it was noted that Opko Health, Inc. (OPKO) had a 45% stake in SciVac. Sci-B-Vac has displaying a performance in 20+ company-sponsored or investigator-initiated trials, dealing with over 5000 who have enrolled while also being administered to over 500,000 patients to date. Results have also been favorable with regard to safety and efficacy profiles according to company data.
http://yhoo.it/1GIvoGm
Wow that's good stuff. Thanks for the info. Any chance you can show me where you found this information? TY
Did a little bit more digging on the company. Apparently their vaccine has already been approved in 10 countries globally and tested in 20 separate clinical trials with over 5,000 participants. It reported the results were 98% effective. Philip Frost has a good eye in this space.
Looks like they got that resolved. Nice piece just mentioned SVACF along with a few other bio plays: http://traders350.com/biotech-stock-watch-2015-scivac-therapeutics-inc-otcmktssvacf-progressive-care-inc-otcmktsrxmd-rxi-pharmaceuticals-corp-nasdaqrxii/723661/
Trending around the 20MA so far. Needs another catalyst in my opinion. I think it would be good to find out what the current status of everything is after that inspection.
Yeah SVACF just popped up on my radar a couple of days ago. Been hearing some talk about it in different chatrooms. Volume seems to have picked up over the last couple of trading days. Could be setting up for a nice potential biotech runner. GLTY
Agreed. The big dogs have a lot more going on but SVACF and the like have a singular focus on this space.
SVACF spread has tightened up today
News would be awesome especially with how thin l2 looks to $0.26+
Agreed. Dr. Frost knows this landscape very well. Volume has been picking up as well. News soon?
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
243
|
Created
|
06/04/15
|
Type
|
Free
|
Moderators |
NEW YORK, NY / ACCESSWIRE / March 20, 2015 / On September 11 last year, a little-known Israeli financial magazine called Globes came out with a report that Dr. Phillip Frost, Chairman and CEO of Opko Health (NYSE:OPK), and then Chairman of Teva Pharmaceuticals (NYSE:TEVA), was interested in moving a private Israeli biotech called SciVac, 45% owned by Opko, into a corporate shell and making it public.
Today, Frost accomplished his goal, as SciVac has been officially acquired by Levon Resources (OTCMKTS:LVNVF), with 68.4% of the new company going to the former private SciVac shareholders and 31.6% going to former Levon shareholders. Since Opko already has a 45% stake in SciVac, that brings its total take in SciVac to 30.8%.
The deal still has to be voted on by current Levon shareholders in April, but is expected to pass.
Opko has had some success taking stakes in biotech companies so far this year. Its recent 8% stake in Cocrystal Pharma (OTCBB:COCP) has jumped 100% since February. Cocrystal is its second largest investment behind private Russian biotech Pharmsynthez.
SciVac's Hepatitis B Vaccine
SciVac is the developer of a third generation hepatitis B vaccine (HBV) called Sci-B-Vac . It is approved in several countries including SciVac's home country of Israel, where it is administered to hundreds of thousands of newborns each year. While first generation HBV vaccines are mostly effective, their effectiveness is still only 90%. In a clinical trial of over 5,000 people, Sci-B-Vac was shown to have an effectiveness of greater than 98% with higher immunogenicity, or immune response in terms of antibodies produced.
The difference between Sci-B-Vac and the current standard-of-care HBV vaccine is that Sci-B-Vac is derived from mammalian cells instead of yeast cells, and carries on it the three main HBV surface antigens instead of just one. It is believed that the 10% of people who do not respond to first generation HBV vaccines are infected with mutant versions of HBV that escape the single antigen vaccine. It is much harder for HBV to mutate all three surface antigens simultaneously to escape Sci-B-Vac.
Despite vaccines available, HBV is still a huge pandemic. According to the World Health Organization, one third of the world's population is infected with HBV, with up to 400M people suffering chronic infections leading to chronic liver disease. 250M of those people are in the Asia-Pacific region alone.
SciVac's next regulatory goal is approval in the United States, where 12M people are infected every year despite the current first generation vaccine available. What regulatory hurdles have to be overcome remains to be seen, given that Sci-B-Vac is already clinically tested and approved in several countries. SciVac will be aiming at the immunocompromised as well as end stage renal disease and HIV patients, as these are patient populations who have special difficulties responding to current HBV vaccines.
Context of Frost's Latest Move Hints at Possible Future Moves
Dr. Frost's latest move comes in the context of several other interesting stock movements that may tip off future deals in the making. In October last year, only one month after Globes reported Frost's interest in taking SciVac public, Levon acquired 35M shares, or 10% of Pershing Gold Corporation, another one of Frost's pet projects of which he has a 15% stake translating to 53.7M shares. Those 35M shares of PGLC will be moving to new entity Spinco, so speculators looking out for the next Frost-related deal should keep an eye on a possible merger between Spinco and Pershing. A similar deal was inked bewteen Pershing and Continental Resources Group in February 2013 where the latter was acquired by Pershing. Continental had a substantial stake in Pershing at the time.
Cocrystal, which is fairly similar to SciVac in that it is focusing on molecularly tailored vaccines, primarily hepatitis C. Cocrystal is also 22% owned by Frost through his investment trust as well as an 8% stake through Opko. Cocrystal has skyrocketed over 100% since February but lacking any obvious catalyst for doing so. Another possible move to watch then is for a deal between Levon, now SciVac, and Cocrystal, which itself was once BioZone, also an Opko investment that was merged into Cocrystal.
With Frost's myriad of moves and deals over the last few years things can get admittedly confusing and make your head spin. The structure of these mergers, however, repeatedly seems to start with Opko at the base and then moves out from there. Opko itself has been on a nearly 100% tear since December. As for Cocrystal's recent 100% move, it may have investors scratching their heads but connecting the dots here could point to the beginning stages of a Frost deal at some point between Cocrystal and SciVac as both specialize in hepatitis vaccines, as well as one between Spinco and Pershing.
Call it equity consolidation with synergies in mind, it certainly is a fascinating chess game.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |